The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents.

Jonathan J DarrowReed F BeallAaron S Kesselheim

Published in: Applied health economics and health policy (2020)

In the pharmaceutical market, the inter partes review process can meaningfully contribute to ensuring that invalid patents do not block timely availability of generic drugs.

Keyphrases

health insurance
drug induced
adverse drug
emergency department
electronic health record